Table 1.
The new direct oral anticoagulants (DOAC) and their mode of action.
| Apixaban (Eliquis®) |
Rivaroxaban (Xarelto®) |
Dabigatran (Pradaxa®) |
Edoxaban (Lixiana®) |
Betrixaban |
|
|---|---|---|---|---|---|
| Action | Anti-FXa | Anti-FXa | Anti-FIIa | Anti-FXa | Anti-FXa |
| Cmax | 3–4 h | 2–3 h | 2 h | 2 h | 3 h |
| T ½ | 8–15 h | 7–11 h | 8–15 h | 10 h | 20 h |
| Elimination | 27% renal 73% hepatic |
33% renal active 33% hepatic 33% renal inactive |
80% rena l20% hepatic |
35% renal 65% hepatic |
5% renal 95% hepatic |
| Dosing | bid | qd | qd, bid | qd | qd |
| Monitoring | no | no | no | no | no |
| Interaction | CYP3A4, P-gp | CYP3A4, P-gp | P-gp | P-gp | CYP3A4 |
| Antidote | Andexanet alfa | Andexanet alfa | Idarucizumab | Andexanet alfa | Andexanet alfa |